Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by DryBoneson Jan 21, 2019 11:10am
134 Views
Post# 29259405

For Sale

For SaleWhat is the real status of PLI?

Who will buy this old car.  A fixer upper for sure, or perhaps sold for parts.

Here we are.  Searching for a new CEO, out of cash and with drug approvals out there some where,  like an re-run X-files mystery.  By the way, the FDA is temporarily shut down.  (that will make for a good excuse some day) 

On top of that the revenue generator PPPS is not yet a going concern as it bleeds money too. Our biggest shareholders have soured on us and probably have given us a year before they take possession of what they may already own, the patents.

So any offers?  We are all waiting while the mismanagement team negotiates from a position of extreme weakness and fatigue.  The challenge is to find a CEO that has some drive and competence and the vision to build a biotech that uniquely specializes in orphan drugs.

Bullboard Posts